WEBULL
WebtradeDownload

Alpha Tau Medical (DRTS) Climbed, So What Is Behind The Fresh Attention?

Simply Wall St · 4d ago

Alpha Tau Medical (NasdaqCM:DRTS) drew fresh attention after signing a memorandum of understanding with Samsung Medical Center in Seoul regarding a potential pancreatic cancer clinical trial, subject to regulatory and ethics approvals.

Alpha Tau Medical’s memorandum of understanding with Samsung Medical Center lands after a powerful run, with the share price up 190.48% year to date and the 1-year total shareholder return at 254.29%. However, the 30-day share price return slipped 5.78%, hinting that short-term momentum has cooled even as longer term interest remains strong.

Scan other high-potential oncology and healthcare stocks showing strong momentum and clinical catalysts in our hand picked 38 healthcare AI stocks tailored for this corner of the market.

Alpha Tau Medical now has a headline partnership story and a share price that has already run hard this year. The real tension for investors is whether that excitement still leaves room at today’s valuation.

Preferred Price-to-Book of 29.4x: Is It Justified?

Alpha Tau Medical is being valued at a steep price-to-book multiple right now, especially when set against both its peers and its current lack of profits. At a last close of $14.03 per share and a market cap of about $1.25b, the stock is carrying expectations that go well beyond the current financial base.

The P/B ratio compares the equity value the market assigns to a business with the accounting value of its net assets. For a clinical-stage oncology group with no meaningful revenue and a reported loss of $92.57m, investors are effectively paying for future potential rather than today’s balance sheet. That makes the P/B metric a quick way to see how much optimism is already in the price.

On that yardstick, Alpha Tau Medical looks expensive. Management’s forecast points to revenue growth of 58.2% per year, compared with a broader US market projection of 13.2% and a 20% high-growth hurdle in the model. Yet the stock trades on a P/B of 29.4x compared with a peer average of 2.3x and a US Medical Equipment industry average of 2.4x. This suggests the market is pricing in a very strong execution path and successful commercialization of Alpha DaRT across several cancer indications.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-book of 29.4x (OVERVALUED)

Still, Alpha Tau Medical carries clear hazards, including ongoing losses of $92.57m and clinical or regulatory setbacks that could quickly puncture today’s premium valuation.

Find out about the key risks to this Alpha Tau Medical narrative.

Next Steps

Big moves in Alpha Tau Medical can stir plenty of emotion, yet the key step is to move quickly, review the underlying data, and decide where you stand. To weigh the trade off between potential upside and the risks flagged so far, start by checking the 1 key reward and 2 important warning signs.

Looking for more Alpha Tau Medical style ideas?

If Alpha Tau Medical has sharpened your focus, do not stop here. Broaden your watchlist with other targeted ideas that fit different parts of your plan.